Trial Profile
Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Mirikizumab (Primary) ; Caffeine; Dextromethorphan; Midazolam; Omeprazole; Warfarin
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 21 Dec 2019 Status changed from active, no longer recruiting to completed.
- 03 Oct 2019 Planned End Date changed from 22 Sep 2019 to 28 Oct 2019.
- 03 Oct 2019 Planned primary completion date changed from 22 Sep 2019 to 28 Oct 2019.